New Roadmap Charts Course for Beta Cell Replacement Therapies in Type 1 Diabetes

Breakthrough T1D has published a comprehensive guide—titled "Future Directions and Clinical Trial Considerations for Novel Islet β-Cell Replacement Therapies for Type 1 Diabetes" in the journal Diabetes—that maps out how the field can move beta cell replacement therapies from laboratory to patients.

Beta cell replacement therapies aim to restore the insulin-producing cells that the immune system attacks in Type 1 diabetes. By replacing or regenerating these cells, the therapy could free people from dependence on external insulin injections or pumps.

The publication brings together perspectives from Breakthrough T1D's research and regulatory experts, along with leading scientists and clinicians across the field, to create a shared roadmap for advancing this work.

Donor islet transplantation has already demonstrated that beta cell replacement can work. People who receive these transplants can achieve insulin independence, meaning their transplanted cells produce enough insulin to manage blood sugar without external insulin.

Early trials testing manufactured islets—lab-created replacements for donated cells—have also shown encouraging results. However, researchers recognize that people with Type 1 diabetes need therapies that are more widely available, more durable, and easier to administer than current approaches.

The publication serves as a guide for the entire ecosystem: researchers developing new therapies, companies bringing them to market, regulatory agencies approving them, clinicians delivering them, and people with Type 1 diabetes who will ultimately use them.

Key focus areas include rethinking how clinical trials are designed to test beta cell replacement therapies and expanding the pool of people who can participate in trials. These changes are essential to ensure therapies reach patients as quickly and safely as possible, and that they benefit everyone who could benefit from them—not just a narrow group.

This publication represents a collaborative effort to address the gaps between current therapies and what people with Type 1 diabetes need. By providing a unified framework, it helps align the work of researchers, industry, regulators, and clinicians toward a shared goal.

While beta cell replacement therapies remain in development, this roadmap reflects the growing momentum in the field and the commitment to making these advances available as sustainably and equitably as possible.

Origin: breakthrought1d.org (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.